Coherus Biosciences | CHRS - Debt


Coherus Biosciences reported $294.92M in Debt for its fiscal quarter ending in March of 2025.





Debt Change Date
AbbVie USD 1000K 70.48B Sep/2025
Acadia Pharmaceuticals USD 54.81M 1.48M Sep/2025
Akebia Therapeutics USD 46.51M 7.82M Mar/2025
ALKERMES USD 71.6M 1.08M Sep/2025
Alnylam Pharmaceuticals USD 1.31B 11.39M Sep/2025
Amarin USD 0 0 Mar/2025
Amgen USD 54.59B 1.62B Sep/2025
Baxter International USD 9.71B 13M Sep/2025
Biogen USD 6.29B 1.7M Dec/2025
BioMarin Pharmaceutical USD 604.24M 375K Sep/2025
Bristol-Myers Squibb USD 51.04B 112M Sep/2025
Coherus Biosciences USD 294.92M 1.25M Mar/2025
Eli Lilly USD 42.51B 2.6B Sep/2025
Fujifilm JPY 922.82B 236.91B Sep/2025
Gilead Sciences USD 24.94B 5M Sep/2025
Ironwood Pharmaceuticals USD 583.99M 14.83M Dec/2024
Merck USD 41.37B 5.97B Sep/2025
Myriad Genetics USD 59.3M 19.7M Mar/2025
Pacira USD 372.19M 4.53M Dec/2025
Perrigo USD 3.64B 7.2M Sep/2025
Pfizer USD 60.85B 78M Sep/2025
PTC Therapeutics USD 286.32M 306K Sep/2025
Regeneron Pharmaceuticals USD 2.71B 400K Sep/2025
Sarepta Therapeutics USD 1.25B 103.69M Sep/2025
Teva Pharmaceutical Industries USD 17.07B 450M Sep/2025
Vertex Pharmaceuticals USD 1.83B 307.4M Sep/2025
Xencor USD 69.27M 1.34M Sep/2025
Zoetis USD 7.27B 482M Sep/2025